Full Text View
Tabular View
Study Results
Related Studies
A Placebo-Controlled Study of Safety and Effectiveness of Myozyme (Alglucosidase Alfa) in Patients With Late-Onset Pompe Disease
This study has been completed.
Study NCT00158600   Information provided by Genzyme

First Received on September 8, 2005.   Last Updated on June 24, 2010   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Pompe Disease (Late-onset)
Acid Maltase Deficiency Disease
Glycogenosis 2
Additional conditions recognized in this trial
Deficiency Diseases
Glycogen Storage Disease
Glycogen Storage Disease Type II
Metabolic Diseases
More general conditions related to this trial
Brain Diseases
Brain Diseases, Metabolic
Brain Diseases, Metabolic, Inborn
Carbohydrate Metabolism, Inborn Errors
Central Nervous System Diseases
Genetic Diseases, Inborn
Lysosomal Storage Diseases
Lysosomal Storage Diseases, Nervous System
Malnutrition
Metabolism, Inborn Errors
Nervous System Diseases
Nutrition Disorders
Interventions listed in this trial
alglucosidase alfa
Placebo
Sponsors listed in this trial
Genzyme


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services